Navigation Links
UCSF stem cell, cancer scientist honored for pioneering studies
Date:6/15/2011

UCSF's Robert Blelloch, MD, PhD, has received the 2011 Outstanding Young Investigator Award from the International Society for Stem Cell Research, for his pioneering research on the role of molecular tools known as microRNAs in embryonic stem cells and cancer.

Blelloch will present his research today, June 15, 2011, at the opening of the ISSCR annual meeting in Toronto (6 p.m. EDT). He will participate in a press briefing at ISSCR tomorrow, June 16 (noon EDT).

MicroRNAs play a subtle, but key, role in regulating the production of proteins, which carry out all cell functions. After a gene's message has been transcripted into messenger RNA, microRNA binds a particular site on the mRNA and ratchets down the amount of protein it produces.

In recent years, research on the role of microRNAs in stem cells and cancer has "exploded," said Blelloch, a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California, San Francisco.

Thanks in part to his team, scientists now know that microRNAs are part of the molecular framework that determines an embryonic stem cell's fate. The cell either will duplicate its genetic material and divide into two identical copies of itself, thus "self renewing," or it will begin to differentiate as a particular type of adult cell, say, a heart muscle cell.

Scientists also know that faulty microRNA function allows unregulated stem cell growth, contributing to cancers. These molecular tools regulate the switch between proliferation and differentiation in both stem cells and cancer.

There are many hundreds of microRNAs, with different roles. Furthermore, each microRNA influences hundreds of messenger RNAs, exerting significant influence on the cell.

During the last few years, Blelloch's team has reported several key findings. In 2008, they reported that microRNAs promote self renewal of embryonic stem cells in mice (Natu
'/>"/>

Contact: Jennifer O'Brien
jennifer.obrien@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Landmark study unlocks stem cell, DNA secrets to speed therapies
2. Stem cell, artificial liver research receives Coulter Foundation funding at NJIT
3. Blood stem cell, leukemia link illuminated in UCSF-led study
4. McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research
5. Go figure: Math model may help researchers with stem cell, cancer therapies
6. How disordered proteins spread from cell to cell, potentially spreading disease
7. Breast cancer treatment resistance linked to signaling pathway
8. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
9. The dietary supplement genistein can undermine breast cancer treatment
10. Saliva proteins could help detection of oral cancer
11. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF stem cell, cancer scientist honored for pioneering studies
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... attained very promising results on their initial investigations of a ... mass spectrometry of a single drop of blood serum, the ... of the patients tested. The results can be found online ... . "Because ovarian cancer is a disease of ...
... As much as 12 percent of the worlds human-caused greenhouse ... charcoal-like substance made from plants and other organic materials. Thats ... and materials were burned to generate energy, concludes a study ... calculations show that biochar can play a significant role in ...
... marine mosasaur Platecarpus , lived in the Cretaceous Period some ... an eel. That theory is debunked in a new paper published ... of scientists have reconceived the animal,s morphology, or body plan, based ... Los Angeles County. The paper was co-authored by ...
Cached Biology News:Initial trials on new ovarian cancer tests exhibit extremely high accuracy 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Nine field ... Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the field ... lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible has ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... focused on the development of autologous cell therapies, announced today ... at the InvestMNT conference held in Minneapolis, Minnesota ... local time. Hall,s presentation will highlight RepliCel,s 18-month milestones including ... Europe , clinical data from both RCT-01 ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... TGH to Enhance Clinical Skills,Development, DENVER, Nov. ... partnership with the University of South Florida (USF) ... Health hospital,partners and for local and national health ... Center is located at Tampa,General Hospital, a major ...
... 10 NeurogesX, Inc.,(Nasdaq: NGSX ), a ... management therapies, announced today that,Anthony DiTonno, President and ... Rodman & Renshaw 10th Annual Healthcare Conference in ... DiTonno and Stephen Ghiglieri,Chief Financial Officer, will also ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
Cached Biology Technology:Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: